Patients in the earliest stage of Alzheimer disease, with very mild symptoms, experienced the lowest risk of complications ...

Rural Georgians may find it difficult to access medication that could slow the progression of Alzheimer's disease, according ...

New data show that lecanemab is well tolerated outside of clinical trial setting, with expected and manageable side effects.

Rural Georgians may find it difficult to access medication that could slow the progression of Alzheimer's disease, according ...

The medication lecanemab was approved by the U.S. FDA to treat Alzheimer’s disease in 2023. Like all medications, lecanemab ...

Lecanemab binds with high affinity to soluble amyloid-beta protofibrils. It won full FDA approval in July 2023 based on trial ...

Harley Street, a famous medical district in London, is an unusual place. It is highly successful, accounting for 40% of the ...

Cassidy’s comments come after Trump signed an executive order to make prescription drug prices in the United States ...

Adoption of lecanemab, a novel infusion treatment for Alzheimer's disease (AD), has been disproportionately higher among ...

Access to a new Alzheimer’s treatment, lecanemab, shows major disparities tied to race, gender, and income. Disparities in ...

The analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab. HealthDay News — Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory ...